2026 ICD-10-CM Diagnosis Code E85.82Wild-type transthyretin-related (ATTR) amyloidosis
ICD-10-CM Codes›E00–E89›E70-E88›E85
- Billable — Valid for Submission
- CC — Complication or Comorbidity
- Risk Adjusts — HCC 50
- Chronic Condition
E85.82 is a billable ICD-10-CM diagnosis code for wild-type transthyretin-related (ATTR) amyloidosis. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 545 through 547. As a secondary diagnosis, it counts as a complication or comorbidity (CC) and moves an inpatient stay to a higher severity level within its MS-DRG family. It does not count, however, when the principal diagnosis is one of 10 closely related codes. Coders also document this condition as age-related amyloidosis. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified nutritional and metabolic disorders.
For Medicare Advantage risk adjustment, E85.82 maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders) under the V28 model, adding a risk factor of about 0.648 for a community, non-dual, aged beneficiary in payment year 2026.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
E85.82 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2026.
Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Age-related amyloidosis
- Cardiac familial non-neuropathic amyloidosis
- Familial cardiomyopathy
- Familial non-neuropathic amyloidosis
- Familial restrictive cardiomyopathy
- Hereditary ATTR amyloidosis
- Infiltrative cardiomyopathy
- Transthyretin related familial amyloid cardiomyopathy
- Wild type ATTR amyloidosis
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- Senile systemic amyloidosis (SSA)
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Myocardial Degeneration
degeneration of myocardial tissue.
Patient EducationClinical
Transthyretin amyloidosis
Transthyretin amyloidosis is a progressive condition characterized by the buildup of abnormal protein deposits called amyloids (amyloidosis) in the body's organs and tissues.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert E85.82 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code History & ChangesHistory
Replacement E85.82 replaces the following previously assigned code(s):
- E85.8 - Other amyloidosis
Questions About E85.82Overview
What is the ICD-10 code for wild-type transthyretin-related (ATTR) amyloidosis?
The ICD-10-CM code for wild-type transthyretin-related (ATTR) amyloidosis is E85.82 (sometimes written as E8582). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
Is E85.82 (Other amyloidosis) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report wild-type transthyretin-related (ATTR) amyloidosis on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does E85.82 group to?
When wild-type transthyretin-related (ATTR) amyloidosis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 545, 546, 547, with relative weights from 0.8362 to 2.4817 depending on complications. Higher weights mean higher Medicare reimbursement.
Is E85.82 a CC or MCC?
CMS lists E85.82 as a CC (complication or comorbidity) for FY 2026. Reported as a secondary diagnosis, it moves the inpatient stay to a higher-weighted DRG within its severity family. It does not count when the principal diagnosis is one of the 10 closely related codes in its exclusion list.
What is the ICD-9 equivalent of E85.82?
Under the General Equivalence Mappings, wild-type transthyretin-related (ATTR) amyloidosis converts to ICD-9-CM 277.39 (amyloidosis NEC). The mapping is approximate, so confirm the match fits the documentation.
What HCC is E85.82?
E85.82 (wild-type transthyretin-related (ATTR) amyloidosis) maps to CMS-HCC Category 50 (Amyloidosis, Porphyria, and Other Specified Metabolic Disorders), commonly written as HCC 50, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2026. It mapped to HCC 23 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. It does not map to any RxHCC in the Part D prescription drug model.
Does E85.82 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, E85.82 adds a risk adjustment factor of about 0.648 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.362 to 0.883 depending on the payment segment). HCC 50 sits at the top of its hierarchy, so no other condition category supersedes it. See the full factor table on the HCC 50 category page.
